Intas Pharmaceuticals in collaboration with its global subsidiaries operating under the Accord brand, has successfully acquired UDENYCA (pegfilgrastim-cbqv) from Coherus BioSciences, Inc.

UDENYCA, a biosimilar to Neulasta (pegfilgrastim), significantly expands Intas and Accord's FDA-approved biosimilar portfolio and accelerates their strategic growth in the global biosimilar market. Accord has a strong footing in the pegfilgrastim market in Europe, having been the first to commercialise a biosimilar pegfilgrastim and the only company to launch an autoinjector. This acquisition further strengthens the company's presence and impact in both the US and international biosimilar landscapes.

With the acquisition, Accord BioPharma, the US specialty business of Intas, continues the commercialisation of UDENYCA to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia. UDENYCA offers three patient-friendly administration options—autoinjector (AI), on-body injector (OBI), and prefilled syringe (PFS)—providing flexibility for treatment at home, on-the-go, or in clinical settings.

The acquisition not only expands Accord BioPharma's product offerings but also brings a wealth of talent from Coherus BioSciences. Key Coherus employees across multiple functions, including Sales, Marketing, Finance, Supply Chain, and Quality and Manufacturing, who have joined Accord BioPharma, will play a crucial role in supply and services continuity/transition and expanding the company's work around UDENYCA.

Chrys Kokino, US President of Accord BioPharma, commented, “The completion of the UDENYCA acquisition marks a pivotal moment for Accord BioPharma, as it not only strengthens our market presence but broadens our capabilities as we endeavour to innovate and expand in the biosimilar space.”

Paul Tredwell, EMENA Executive Vice-President of Accord, added, “With the Accord Biopharma team now fully commercializing UDENYCA in three different formulations, this development strengthens Accord's offering and advances our goal of becoming the world's leading supplier of pegfilgrastim.”

Binish Chudgar, Chairman and Managing Director of Intas Pharmaceuticals, said, “We are energised by this addition to Accord BioPharma's portfolio because it exemplifies our commitment to improving patient access to high-quality treatments that meet the evolving needs of both patients and healthcare providers. This acquisition cements our position as a global leader in pegfilgrastim and allows us to further expand our specialty division across key international markets.”